Iodixanol

Generic Name: Iodixanol

Brand Names: Visipaque, Visipaque 270, Visipaque 320

Drug Type: Small Molecule

Chemical Formula: C_₃₅H_₄₄I_₆N_₆O_₁₅

CAS Number: 92339-11-2

Unique Ingredient Identifier: HW8W27HTXX

Background: Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.

Indication: Iodixanol is a contrast agent during coronary angiography.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography

Phase 4

Conditions: Contrast Media Reaction
Coronary Artery Disease

Interventions: Drug: Iodixanol
Drug: Iohexol

First Posted Date: 2021-10-01

Last Posted Date: 2021-10-25

Lead Sponsor: Minneapolis Heart Institute Foundation

Target Recruit Count: 62

Registration Number: NCT05065073

Locations: 🇺🇸
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States

Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium

Completed

Conditions: ST-segment Elevation Myocardial Infarction
Coronary Artery Disease

Interventions: Drug: Iodixanol

First Posted Date: 2018-09-14

Last Posted Date: 2022-01-11

Lead Sponsor: GE Healthcare

Target Recruit Count: 2755

Registration Number: NCT03671603

Locations: 🇨🇳
Dongguan Kanghua Hospital, Guangdong, Guangdong, China
🇨🇳
Wuhan Asia Heart Hospital, Wuhan, Hubei, China
🇨🇳
China-Japan Friendship Hospital of Jilin University, Changchun, Jilin, China

and more 33 locations

Pediatric Risk of Hypothyroidism With Iodinated Contrast Media

Phase 4

Withdrawn

Conditions: Hypothyroidism

Interventions: Drug: Iohexol
Drug: Iodixanol
Drug: Iopromide
Drug: Ioversol

First Posted Date: 2018-08-15

Last Posted Date: 2022-04-20

Lead Sponsor: GE Healthcare

Registration Number: NCT03631771

A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease

Phase 4

Terminated

Conditions: Chronic Kidney Diseases

Interventions: Drug: Placebos
Drug: Visipaque

First Posted Date: 2017-04-18

Last Posted Date: 2019-12-17

Lead Sponsor: GE Healthcare

Target Recruit Count: 4

Registration Number: NCT03119662

Locations: 🇺🇸
Central Arkansas Veteran's Healthcare System, Little Rock, Arkansas, United States
🇧🇪
UZ Leuven, Leuven, Belgium
🇺🇸
: Aventiv Research Inc., Mesa, Arizona, United States

and more 26 locations

Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN

Not Applicable

Conditions: Cardio-Renal Syndrome

Interventions: Procedure: Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate
Drug: Visipaque
Drug: 0.9% sodium chloride ﬂuid administration
Drug: isosorbide dinitrate

First Posted Date: 2016-03-24

Last Posted Date: 2016-03-24

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 400

Registration Number: NCT02718521

Locations: 🇨🇳
Chinese People's Liberation Army General Hospital, Peking, Beijing, China

Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy

Not Applicable

Completed

Conditions: Cardio-Renal Syndrome

Interventions: Procedure: hydration
Drug: Visipaque
Drug: 0.9% sodium chloride ﬂuid administration
Device: 5-French catheter

First Posted Date: 2015-04-01

Last Posted Date: 2015-04-01

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 264

Registration Number: NCT02405377

Locations: 🇨🇳
Chinese People's Liberation Army General Hospital, Peking, Beijing, China

Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)

Phase 3

Completed

Conditions: Coronary Computed Tomographic Angiography

Interventions: Drug: Isovue 370
Drug: Visipaque 320

First Posted Date: 2014-06-24

Last Posted Date: 2014-08-15

Lead Sponsor: Duke University

Target Recruit Count: 35

Registration Number: NCT02171247

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Ioxaglate
Drug: Iodixanol
Drug: Bivalirudin

First Posted Date: 2013-05-08

Last Posted Date: 2016-04-06

Lead Sponsor: NYU Langone Health

Target Recruit Count: 100

Registration Number: NCT01848899

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction

Phase 4

Conditions: Kidney Failure, Chronic

Interventions: Drug: iodixanol
Drug: iopromide

First Posted Date: 2012-04-18

Last Posted Date: 2013-10-16

Lead Sponsor: Yong Huo

Target Recruit Count: 200

Registration Number: NCT01580046

Locations: 🇨🇳
The First Affiliated Hospital Of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳
Pla Navy General Hospital, Beijing, China

and more 16 locations

Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography

Phase 4

Completed

Conditions: Drug Safety

Interventions: Drug: Iopamidol
Drug: Iodixanol

First Posted Date: 2011-11-21

Last Posted Date: 2014-06-11

Lead Sponsor: GE Healthcare

Target Recruit Count: 255

Registration Number: NCT01475097

Locations: 🇺🇸
GE Healthcare, Princeton, New Jersey, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy